Assessing Gut Microbiome Changes Before and After an Oral Nutritional Supplement Intake Using the SIMBA Capsule in Diabetic Participants

NCT06704022 | Not Yet Recruiting Phase 1 DMC

• 1 other identifier: NIMCSF276
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single-arm interventional clinical study, the primary objective is to assess the changes in the small intestinal (SI) metagenomic profile of in diabetic participants from baseline to midpoint and endpoint in response to the ONS intervention. The study population is Type 2 Diabetes (T2D) participants (n=30) who will ingest an Oral Nutritional Supplement (ONS) .

Conditions

Type 2 Diabetes

Keywords

oral nutritional supplement; microbiome; small intestine

Outcome Measures

Primary Outcomes (1)

• Primary Outcome

  To assess changes in small intestinal metagenomic profile in Type 2 diabetic participants from baseline to midpoint and endpoint in response to the ONS intervention, as measured using the SIMBA capsule.

  Compared at intervention from baseline, midpoint, to endpoint (completion), an average of 6 weeks

Secondary Outcomes (6)

• Secondary 1

  Compared from baseline, midpoint to endpoint (completion), an average of 6 weeks

• Secondary 2

  Compared from baseline, midpoint to endpoint (completion), an average of 6 weeks

• Secondary 3

  Compared from baseline, midpoint to endpoint (completion), an average of 6 weeks

• Secondary 4

  Compared from baseline, midpoint to endpoint (completion), an average of 6 weeks

• Secondary 5

  Compared from baseline, midpoint to endpoint (completion), an average of 6 weeks

Study Arms (1)

Interventional Arm

EXPERIMENTAL

Ingestion of the ONS

Dietary Supplement: Oral nutritional supplement

Interventions

Oral nutritional supplement DIETARY_SUPPLEMENT

Consumption of the oral nutritional supplement

Interventional Arm

Eligibility Criteria

• Age: 40 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Has type 2 diabetes as evidenced by their medical history charts and is able to maintain number of medications, type and dose throughout the duration of the study.
• Has HbA1c ≥ 6.5% and ≤ 9.5% based on a blood sample collected at the Screening Visit, documented within the past month or referred by a medical doctor.
• Normal to overweight (BMI 20-29.9).
• Weight is stable (has maintained current body weight within 3 kg) for the two months prior to the Baseline Visit.
• Is taking a maximum of 3 oral anti-diabetic drugs, one of which must be Metformin. Other class of medications permitted include: Sulfonylurea, SGLT2 inhibitors, and DPP4 inhibitors.
• Either a male or a non-pregnant, non-lactating female, at least 6 weeks postpartum prior to the Baseline Visit.
• Willingness to follow the protocol as described, including consumption of study product per the protocol and completing any forms/questionnaires needed throughout the study.
• The participant is willing to refrain from taking non-study diabetes-specific oral nutritional formulas over the entire course of the study.
• Willing to maintain their diet and physical activity levels during the study.
• Able to swallow a 25mm length and 9mm width sized capsule.
• At least a four-week washout period between the completion of a previous research study that required ingestion of any study food or drug and their start in the current study. Signed Informed Consent; willing and able to comply with study procedures

You may not qualify if:

• Confirmed type 1 diabetes and/or had a history of diabetic ketoacidosis.
• Use of exogenous insulin or GLP1 agonists for glucose control.
• Using diabetes-specific oral nutritional supplements(s), (e.g. Glucerna®, Boost etc.) defined as more than one eating occasion per week within the past 4 weeks (those users who can stop using such products for ≥4 weeks before baseline visit need not be excluded).
• Follows a non-typical eating pattern such as very low carbohydrate diet (e.g., Adkins diet, ketogenic diet, high protein diet).
• Has eating disorder, severe dementia or delirium, history of significant neurological or psychiatric disorder, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures in the opinion of the investigators.
• Galactosemia and lactose intolerance
• A chronic disease which in the opinion of the investigator, would adversely affect study safety or outcome. Such as, but not limited to
• A significant cardiovascular event within 6 months prior to study entry or history of congestive heart failure, per physician evaluation.
• End-stage organ failure (such as end-stage renal disease) or is post-organ transplant.
• Current or history of renal disease or on dialysis or severe gastroparesis.
• Current diagnosed hepatic disease such as liver cirrhosis or late-stage liver fibrosis. Participants with prevalent angina will not be excluded.
• A chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis C, or HIV.
• Subject has current active malignant disease or was treated within the last 6 months for cancer, except basal or squamous cell skin carcinoma, prior to enrollment.
• Taking any herbals, dietary supplements, or medications during the past four weeks prior to baseline visit that could profoundly affect (in the opinion of the principal investigator or site physician) blood glucose, body weight, muscle, metabolism, appetite or microbiome (e.g. orlistat, contrave) (naltrexone/bupropion), Qsymia (phentermine/topiramate), Belviq (lorcaserin), incretin mimetics, other drugs indicated for weight loss, cannabis, glucocorticoids, prebiotics and probiotic supplements). Those users who have stopped using such supplements/ medications for ≥4 weeks prior to baseline need not be excluded).
• Use of any medications in the week prior to the screening study visit, unless part of regular treatment, that could substantially alter gastrointestinal motor function (e.g., opioids, anticholinergics, GLP-1 analogues); laxative use is allowed if it is kept unchanged in the week prior to the SIMBA capsule ingestion timepoints. Proton pump inhibitors (PPIs) are allowed provided a wash-out period of 48 hours is respected before swallowing the SIMBA capsules and PPI treatment is resumed only 4 hours thereafter.

Sponsors & Collaborators

• Nimble Science Ltd.: lead
• Alberta Obesity Centre: collaborator

Study Sites (1)

Nimble Science

Calgary, Alberta, T2L 1Y8, Canada

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

Dietary Supplements

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Food; Diet, Food, and Nutrition; Physiological Phenomena; Food and Beverages

Central Study Contacts

Gwen Duytschaever, PhD

CONTACT

8664934633; clinical@nimblesci.com

Isaac Wong, MBT

CONTACT

8664934633; clinical@nimblesci.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 20, 2024
• First Posted: November 25, 2024
• Study Start: September 1, 2025
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): August 1, 2026
• Last Updated: August 11, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)